ISCT Committee Paper|Articles in Press

Early Stage Professionals Committee Proceedings from the International Society for Cell & Gene Therapy 2022 Annual Meeting

Published:March 10, 2023DOI:


      In this Committee Proceedings, representatives from the Early Stage Professional (ESP) committee highlight the innovative discoveries and key take-aways from oral presentations at the 2022 International Society for Cell and Gene Therapy (ISCT) Annual Meeting that cover the following subject categories: Immunotherapy, Exosomes and Extracellular Vesicles, HSC/Progenitor Cells and Engineering, Mesenchymal Stromal Cells, and ISCT Late-Breaking Abstracts.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Cytotherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Gross G.
        • Waks T.
        • Eshhar Z.
        Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity.
        Proc. Natl. Acad. Sci. U. S. A. 1989; 86: 10024-10028
        • Finer M.H.
        • Dull T.J.
        • Qin L.
        • Farson D.
        • Roberts M.R.
        kat: a high-efficiency retroviral transduction system for primary human T lymphocytes.
        Blood. 1994; 83: 43-50
        • Munshi N.C.
        • et al.
        Idecabtagene vicleucel in relapsed and refractory multiple myeloma.
        N. Engl. J. Med. 2021; 384: 705-716
        • Shah N.
        • Chari A.
        • Scott E.
        • Mezzi K.
        • Usmani S.Z.
        B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches.
        Leukemia. 2020; 34: 985-1005
        • Westin J.R.
        • et al.
        Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed/refractory aggressive B-cell lymphomas: observations from the JULIET, ZUMA-1, and transcend trials.
        Am. J. Hematol. 2021; 96: 1295-1312
        • Roman C.M.
        • et al.
        TNFR2 As a Target to Improve CD19-Directed CART Cell Fitness and Antitumor Activity in Large B Cell Lymphoma.
        Blood. 2021; 138: 901
        • Maude S.L.
        • et al.
        Tisagenlecleucel in children and young adults with B-Cell lymphoblastic leukemia.
        N. Engl. J. Med. 2018; 378: 439-448
        • Silvestre R.N.E.J.
        • de Azevedo J.T.T.C.
        • Tonn T.
        • Picanço-Castro V.
        Immunotherapy: Late breaking abstract: CD19-CAR NK cells co-expressing IL15/IL15Rα show enhanced cytotoxicity against B-cell leukemia.
        Cytotherapy. 2022; 24
        • Hill L.C.R.R.
        • Smith T.S.
        • et al.
        Safety and anti-tumor activity of CD5 CAR T-cells in patients with relapsed/refractory T-cell malignancies.
        Blood. 2019; 134
        • Ma R.W.M.
        • Chaumette A.
        Immunotherapy: mechanisms regulating the resistance of normal T-cells to CD5 CAR-mediated cytotoxicity.
        Cytotherapy. 2022; 24
        • Abdou Y.
        Hematopoietic stem/progenitor cells and engineering: a phase 1, first in human (FIH) study of adenovirally transduced autologous macrophages engineered to contain an ANTI-HER2 chimeric antigen receptor (CAR) in subjects with HER2 overexpressing solid tumors.
        Cytotherapy. 2022; 24
        • Klichinsky M.
        • et al.
        Human chimeric antigen receptor macrophages for cancer immunotherapy.
        Nat. Biotechnol. 2020; 38: 947-953
        • Sloas C.
        • Gill S.
        • Klichinsky M.
        Engineered CAR-macrophages as adoptive immunotherapies for solid tumors.
        Front. Immunol. 2021; 12783305
        • Saha A.
        DUOC-01, a cell therapy product derived from human cord blood, accelerates remyelination.
        STEM CELLS Translational Medicine. 2018; 7: S5
        • Saha A.
        DUOC-01, a cord blood derived cell therapy product, ameliorates experimental autoimmune encephalomyelitis, a murine model for multiple sclerosis.
        Cytotherapy. 2020; 22: S31-S32
        • Xu L.
        Hematopoietic stem/progenitor cells and engineering: human umbilical cord blood derived cell therapy product, DUOC-01, promotes remyelination by driving the differentiation of OPC.
        Cytotherapy. 2022; 24
        • R W.
        Hematopoietic stem/progenitor cells and engineering: from harmful to USEFUL: exploiting a leukemic transcription factor for large-scale ex vivo manufacture of human macrophages.
        Cytotherapy. 2022; 24
        • Welsh J.A.
        • et al.
        MIFlowCyt-EV: a framework for standardized reporting of extracellular vesicle flow cytometry experiments.
        J Extracell Vesicles. 2020; 91713526
        • Welsh J.A.
        MPAPASS software enables stitched multiplex, multidimensional ev repertoire analysis and a standard framework for reporting bead-based assays.
        Cell Rep Methods. 2022; 2100136
        • Sutherland D.R.
        • Anderson L.
        • Keeney M.
        • Nayar R.
        • Chin-Yee I.
        The ISHAGE guidelines for CD34+ cell determination by flow cytometry. international society of hematotherapy and graft engineering.
        J. Hematother. 1996; 5: 213-226
        • Thiago L.S.
        • Sutherland D.R.
        CD34(+) B-cell progenitors in mobilized peripheral blood apheresis collections: implications for flow cytometric assessment of graft adequacy.
        Cytotherapy. 2015; 17: 689-691
        • Sun M.S.
        • Schwister G.
        Hematopoietic stem/progenitor cells and engineering: it's time to exclude hematogones from the result of CD34+ hematopoietic stem cell enumeration in HPC product.
        Cytotherapy. 2022; 24
        • Ondrejka S.L.
        • et al.
        Hematogones Contained in CD34+ Apheresis Products for Hematopoietic Progenitor Cell Transplantation Have No Adverse Impact On Engraftment Outcomes.
        Blood. 2012; 120: 3022
        • Al-Riyami A.Z.
        Hematopoietic stem/progenitor cells and engineering: a machine learning model that incorporates CD45 mean fluorescence intensity (MFI) and cell composition predicts poor viability of hematopoietic progenitor cells after freeze–thaw.
        Cytotherapy. 2022; 24
        • Marklein R.A.
        Morphological profiling using machine learning reveals emergent subpopulations of interferon-gamma-stimulated mesenchymal stromal cells that predict immunosuppression.
        Cytotherapy. 2019; 21: 17-31
        • Mehrian M.
        • et al.
        Predicting in vitro human mesenchymal stromal cell expansion based on individual donor characteristics using machine learning.
        Cytotherapy. 2020; 22: 82-90
        • Naghizadeh A.
        In vitro machine learning-based CAR T immunological synapse quality measurements correlate with patient clinical outcomes.
        PLoS Comput. Biol. 2022; 18e1009883
        • Auletta J.J.
        Meeting the demand for unrelated donors in the midst of the COVID-19 pandemic: rapid adaptations by the national marrow donor program and its network partners ensured a safe supply of donor products.
        Transplant Cell Ther. 2021; 27: 133-141
        • Dholaria B.
        • Malki M.M.A.
        • Artz A.
        • Savani B.N.
        Securing the graft during pandemic: are we ready for cryopreservation for all?.
        Biol. Blood Marrow Transplant. 2020; 26: e145-e146
        • Dopico J.T.
        Hematopoietic stem/progenitor cells and engineering: cryopreservation of unrelated donor peripheral blood hematopoietic cell products does not impair platelet and neutrophil engraftment.
        Cytotherapy. 2022; 24
        • Dopico J.T.
        Hematopoietic stem/progenitor cells and engineering: evaluation of cell concentration, transit time and cryopreservation of unrelated donor products on engraftment.
        Cytotherapy. 2022; 24
        • Javed R.
        Hematopoietic stem/progenitor cells and engineering: HALF-TRUTH: graft cryopreservation does not impact engraftment after allogeneic hematopoietic cell transplant (ALLO-HCT)—a single center experience from India.
        Cytotherapy. 2022; 24
        • Thompson T.Z.
        Hematopoietic stem/progenitor cells and engineering: 20-year hematopoietic progenitor cell stability; the Mayo Clinic experience.
        Cytotherapy. 2022; 24
        • Alotaibi A.S.
        • et al.
        Fresh vs. frozen allogeneic peripheral blood stem cell grafts: a successful timely option.
        Am. J. Hematol. 2021; 96: 179-187
        • Devine S.M.
        Transplantation of allogeneic cryopreserved hematopoietic cell grafts during the COVID-19 pandemic: a national marrow donor program perspective.
        Am. J. Hematol. 2021; 96: 169-171
        • Walker J.
        Hematopoietic stem/progenitor cells and engineering: characterizing red blood cell properties for improved stem cell collections in sickle cell disease.
        Cytotherapy. 2022; 24
        • Lucas A.T.
        Hematopoietic stem/progenitor cells and engineering: early CD4 T cell immune reconstitution after HCT is associated with reduced non-relapse related mortality but not with decreased relapse risk.
        Cytotherapy. 2022; 24
        • Ogonek J.
        • et al.
        Immune reconstitution after allogeneic hematopoietic stem cell transplantation.
        Front. Immunol. 2016; 7: 507
        • Muhsen I.N.
        Hematopoietic stem/progenitor cells and engineering: late breaking abstract: allogeneic donor-derived CD19–chimeric antigen receptor (CAR) T cells for relapsed B-cell malignancies after hematopoietic stem cell transplantation.
        Cytotherapy. 2022; 24
        • Oza S.P.
        Hematopoietic stem/progenitor cells and engineering: use and cost analysis of hematopoietic progenitor cells stored for future use in patients with multiple myeloma.
        Cytotherapy. 2022; 24
        • Fung M.
        • Yuan Y.
        • Atkins H.
        • Shi Q.
        • Bubela T.
        Responsible translation of stem cell research: an assessment of clinical trial registration and publications.
        Stem Cell Reports. 2017; 8: 1190-1201
        • Galipeau J.
        • Sensebe L.
        Mesenchymal stromal cells: clinical challenges and therapeutic opportunities.
        Cell Stem Cell. 2018; 22: 824-833
        • Krampera M.
        • Le Blanc K.
        Mesenchymal stromal cells: putative microenvironmental modulators become cell therapy.
        Cell Stem Cell. 2021; 28: 1708-1725
        • Gowen A.
        • Shahjin F.
        • Chand S.
        • Odegaard K.E.
        • Yelamanchili S.V.
        Mesenchymal stem cell-derived extracellular vesicles: challenges in clinical applications.
        Front. Cell Dev. Biol. 2020; 8: 149
        • Borger V.
        • et al.
        Mesenchymal stem/stromal cell-derived extracellular vesicles and their potential as novel immunomodulatory therapeutic agents.
        Int. J. Mol. Sci. 2017; 18: 1450
        • Loyer X.
        • et al.
        Intra-cardiac release of extracellular vesicles shapes inflammation following myocardial infarction.
        Circ. Res. 2018; 123: 100-106
        • de Witte S.F.H.
        • et al.
        Immunomodulation by therapeutic mesenchymal stromal cells (MSC) is triggered through phagocytosis of MSC by monocytic cells.
        Stem Cells. 2018; 36: 602-615
        • Min H.
        • et al.
        Mesenchymal stromal cells reprogram monocytes and macrophages with processing bodies.
        Stem Cells. 2021; 39: 115-128
        • Galleu A.
        • et al.
        Apoptosis in mesenchymal stromal cells induces in vivo recipient-mediated immunomodulation.
        Sci. Transl. Med. 2017; 9: 416
        • Enes S.R.
        • et al.
        Healthy versus inflamed lung environments differentially affect mesenchymal stromal cells.
        Eur. Respir. J. 2021; 58: 2004149
        • Pang S.H.M.
        • et al.
        Mesenchymal stromal cell apoptosis is required for their therapeutic function.
        Nat. Commun. 2021; 12: 6495
        • Lv B.
        • et al.
        Immunotherapy: reshape the tumor immune microenvironment.
        Front. Immunol. 2022; 13844142
        • Lamb M.G.
        • Rangarajan H.G.
        • Tullius B.P.
        • Lee D.A.
        Natural killer cell therapy for hematologic malignancies: successes, challenges, and the future.
        Stem Cell Res Ther. 2021; 12: 211
        • Rouce R.H.
        • et al.
        The TGF-beta/SMAD pathway is an important mechanism for NK cell immune evasion in childhood B-acute lymphoblastic leukemia.
        Leukemia. 2016; 30: 800-811
        • Verrecchia F.
        • Redini F.
        Transforming growth factor-beta signaling plays a pivotal role in the interplay between osteosarcoma cells and their microenvironment.
        Front. Oncol. 2018; 8: 133
        • Burga R.A.
        • et al.
        Engineering the TGFbeta receptor to enhance the therapeutic potential of natural killer cells as an immunotherapy for neuroblastoma.
        Clin. Cancer Res. 2019; 25: 4400-4412
        • Foltz J.A.
        • Moseman J.E.
        • Thakkar A.
        • Chakravarti N.
        • Lee D.A.
        TGFbeta imprinting during activation promotes natural killer cell cytokine hypersecretion.
        Cancers (Basel). 2018; 10: 423
        • Thakkar A.D.W.
        • Nielsen D.
        Immunotherapy: late breaking abstract: a phase I study of universal donor TGFβ-imprinted NK cell therapy in combination with carboplatin for canine osteosarcoma.
        Cytotherapy. 2022; 24
        • Chaudhry K.G.A.
        • Dowlati E.
        Immunotherapy: B7H3-CAR NK cells and DNR co-transduced NK shows maintain their potency against TGF-B mediated immune suppression.
        Cytotherapy. 2022; 24
        • Dong E.
        • Du H.
        • Gardner L.
        An interactive web-based dashboard to track COVID-19 in real time.
        Lancet Infect. Dis. 2020; 20: 533-534
        • Diao B.
        • et al.
        Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19).
        Front. Immunol. 2020; 11: 827
        • Bollard C.M.
        • Heslop H.E.
        T cells for viral infections after allogeneic hematopoietic stem cell transplant.
        Blood. 2016; 127: 3331-3340
        • Flower A.A.J.
        • Harrison L.
        • et al.
        The safety and efficacy of targeted virus specific cytotoxic T-lymphocytes (vsCTL) manufactured by the IFN-G cytokine capture system (CCS) for the treatment of refractory adenovirus (ADV), cytomegalovirus (CMV), Epstein Barr virus (EBV) and BK virus (BKV) in children, adolescents and young adults (CAYA) after allogeneic hematopoietic stem cell transplantation (Allo-HSCT), solid organ transplantation (SOT), or with primary immunodeficiency (PID) (IND# 17449).
        Biol. Blood Marrow Transplant. 2020; 26(3):S72-S73
        • Houghtelin A.
        • Bollard C.M.
        Virus-specific T cells for the immunocompromised patient.
        Front. Immunol. 2017; 8: 1272
        • Kallay K.
        • et al.
        Early experience with CliniMACS Prodigy CCS (IFN-gamma) system in selection of virus-specific T cells from third-party donors for pediatric patients with severe viral infections after hematopoietic stem cell transplantation.
        J. Immunother. 2018; 41: 158-163
        • Keller M.D.
        • Bollard C.M.
        Virus-specific T-cell therapies for patients with primary immune deficiency.
        Blood. 2020; 135: 620-628
        • Leen A.M.
        • et al.
        Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation.
        Blood. 2013; 121: 5113-5123
        • Nelson A.S.
        • et al.
        Virus-specific T-cell therapy to treat BK polyomavirus infection in bone marrow and solid organ transplant recipients.
        Blood Adv. 2020; 4: 5745-5754
        • Prockop S.
        • et al.
        Off-the-shelf EBV-specific t cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation.
        J. Clin. Invest. 2020; 130: 733-747
        • Rubinstein J.D.
        • et al.
        Virus-specific T cells for adenovirus infection after stem cell transplantation are highly effective and class II HLA restricted.
        Blood Adv. 2021; 5: 3309-3321
        • Tzannou I.
        • et al.
        Off-the-shelf virus-specific T cells to treat BK virus, human herpesvirus 6, cytomegalovirus, Epstein–Barr virus, and adenovirus infections after allogeneic hematopoietic stem-cell transplantation.
        J. Clin. Oncol. 2017; 35: 3547-3557
        • Papadopoulou A.K.G.
        • Papadopoulou E.
        Immunotherapy: safety and efficacy of SARS-CoV-2-specific T cells as adoptive immunotherapy for high-risk COVID-19 patients: a phase I/II, randomized clinical trial.
        Cytotherapy. 2022; 24
        • Bernaldo-de-Quirós E.
        • et al.
        A novel GMP protocol to produce high-quality Treg cells from the pediatric thymic tissue to be employed as cellular therapy.
        Front. Immunol. 2022; 13893576
        • de Quirós E.B.C.M.
        • ozar Beatriz
        • et al.
        A novel GMP Protocol to Produce High-Quality Treg Cells From the Pediatric Thymic TIssue to Be EMpoyed as Cellular Therapy.
        Front Immunol. 2022; 13: 893576